Metspharma

Metspharma is a South Korean specialty pharmaceutical company dedicated to the licensing, registration, and commercialization of orphan drugs and treatments for rare diseases. Founded in 2014, the company acts as a strategic bridge for global biotechnology firms seeking to enter the Korean market, providing specialized expertise in regulatory affairs and reimbursement. Its commercial portfolio includes essential therapies for metabolic disorders, such as Wilson's disease and urea cycle disorders, as well as oncology and respiratory conditions. By partnering with international innovators like Recordati Rare Diseases and Chiesi, Metspharma ensures that patients with high unmet medical needs in South Korea have access to life-saving medications.